University Health Network

University of Toronto

Other

Mcmaster University

Shanghaitech University

Modmab Therapeutics Corporation

Sidhu, Sachdev

Angers, Stephane

Moffat, Jason

Robitaille, Melanie

Guohua Pan

Miklos Feher

Heinz W Pauls

Peter Brent Sampson

Yong Liu

Bryan T Forrest

Sachdev Singh Sidhu

Radoslaw Laufer

Sze-Wan Li

Jason Moffat

Louise G Edwards

Narendra Kumar B Patel

Stephane Angers

Jacqueline M Mason

Amandeep Gakhal

Yi Yao

Xin Wei

Melanie Robitaille

Tak Wah Mak

Yunhui Lang

Shane Miersch

Haiming Huang

Sheila K Singh

Shusu Liu

Donghui Wu

Sachedv S Sidhu

Jarrett Adams

Rashida Williams

Chitra Venugopal

Zachary Steinhart

Xiaowei Wang

Xiaoyu Zhang

Parvez Vora

Kathrin Zaugg

Narendra Kumar Patel

Sachdev Sidhu

Sze-Wan Ll

Provided are antibodies or fragments thereof having binding specificity to anti-IL-18 receptor alpha or beta. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and inflammatory and autoimmune diseases are also provided.

Human antibodies to human interleukin 18 receptor alpha or beta

This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.

CD133-binding agents and uses thereof

The present disclosure is directed to novel FZD5-binding agents and methods and uses thereof for treating a disease or disorder associated with aberrant expression or activity of Frizzled protein.

Frizzled5 protein-binding agents

This invention provides monoclonal antibodies that recognize one or more Frizzled receptors. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Antibodies against Frizzled receptor

Antibodies against frizzled receptor

Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist.

Methods of targeting PTEN mutant diseases and compositions therefor

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Kinase inhibitors and method of treating cancer with same

Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

The present invention is directed to a compound is represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof. 

Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer

The present invention relates to methods for treating cancer by administering a therapeutically effective amount of compound of formula (I), such as selective NPY5R antagonist MK-0557 (trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H), 1'-cyclohexane]-4&#x2032;-carboxamide), or a pharmaceutically acceptable salt thereof, to a subject in need thereof The methods can further comprise administering a chemotherapeutic agent to the subject in need thereof. 

Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist

A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. 

Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer

The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject.

Methods of inhibiting tumor growth using TTK antagonists

Kinase inhibitors and method of treating cancer

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein. 

A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. 

Inhibitors of carnitine palmitoyltransferase and treating cancer

Growing community of inventors

Oakville, Canada

Guohua Pan